CoChat

Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study

Open access
Terauchi, Yasuo, Satoi, Yoichi, Takeuchi, Masakazu, Imaoka, Takeshi · 2014 · Endocrine Journal
Cited by 50

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

The aim of this study was to evaluate the dose-dependent effect of dulaglutide, a glucagon-like peptide-1 receptor agonist, on glycaemic control in Japanese patients with type 2 diabetes mellitus who were treated with diet/exercise or oral antidiabetic drug monotherapy. In this randomised, double-blind, placebo-controlled, parallel-group, 12-week study, patients received once weekly subcutaneous dulaglutide doses of 0.25, 0.5, or 0.75 mg (DU 0.25, DU 0.5, and DU 0.75, respectively) or placebo (n=36, 37, 35, and 37, respectively). The primary measure was change from baseline in glycated haemoglobin (HbA1c; %) at 12 weeks. Continuous variables were analysed using a mixed-effects model for repeated measures. Significant dose-dependent reductions in HbA1c were observed (least squares mean difference versus placebo [95% confidence interval]): DU 0.25=-0.72% (-0.95, -0.48), DU 0.5=-0.97% (-1.20, -0.73), and DU 0.75=-1.17% (-1.41, -0.93); p<0.001. Significant improvements in plasma glucose (PG), both fasting and average 7-point self-monitored blood glucose, were also observed with dulaglutide versus placebo (p<0.001). Dulaglutide was well-tolerated. Gastrointestinal adverse events (AEs) were more common in dulaglutide-treated patients, with nausea the most frequent (8 [5.5%]). Few dulaglutide-treated patients discontinued due to AEs (4 [3.7%]), and no serious AEs related to study medication occurred. Three patients (DU 0.5=1 and DU 0.75=2) reported asymptomatic hypoglycaemia (PG ≤70 mg/dL). The observed dose-dependent reduction in HbA1c and acceptable safety profile support further clinical development of dulaglutide for treatment of type 2 diabetes mellitus in Japan.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1507/endocrj.ej14-0147

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 18

  1. 1. Garber AJ (2011) Incretin therapy - present and future. Rev Diabet Stud 8: 307-322. · DOI
  2. 3. Combes J, Borot S, Mougel F, Penfornis A (2011) The potential role of glucagon-like peptide-1 or its analogues in enhancing glycaemic control in critically ill adult patients. Diabetes Obes Metab 13: 118-129. · DOI
  3. 4. Fineman MS, Cirincione BB, Maggs D, Diamant M (2012) GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 14: 675-688. · DOI · Paper page
  4. 7. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, et al. (2011) An overview of once-weekly glucagon-like peptide-1 receptor agonists - available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 13: 394-407. · DOI · Paper page
  5. 8. Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, et al. (2010) Engineering and characterization of the long-acting glucagonlike peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 26: 287-296. · DOI · Paper page
  6. 13. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, et al. (2012) Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med 29: 1260-1267. · DOI · Paper page
  7. 14. Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, et al. (2011) LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 13: 434-438. · DOI · Paper page
  8. 15. Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, et al.; EGO Study Group (2011) The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab 13: 418-425. · DOI · Paper page
  9. 16. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K (2008) Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 81: 161-168. · DOI
  10. 18. Yabe D, Seino Y (2011) Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference. Clin Med Insights Endocrinol Diabetes 4: 47-62. · DOI
  11. 19. Fujimoto WY, Boyko EJ, Hayashi T, Kahn SE, Leonetti DL, et al. (2012) Risk factors for type 2 diabetes: lessons learned from Japanese Americans in Seattle. J Diabetes Investig 3: 212-224. · DOI
  12. 20. Hirose T, Kawamori R (2005) Diabetes in Japan. Curr Diab Rep 5: 226-229. · doi:10.1007/s11892-005-0013-4
  13. 21. Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators (2010) Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 27: 1024-1032. · DOI · Paper page
  14. 22. Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, et al. (2009) Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 56: 415-424. · DOI · Paper page
  15. 23. Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T (2012) Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther 34: 1892-1908. · DOI
  16. 24. Ji L, Onishi Y, Ahn CW, Agarwal P, Chou CW, et al. (2013) Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with Type 2 diabetes mellitus. J Diabetes Investig 4: 53-61. · DOI · Paper page
  17. 25. Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators (2012) Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 14: 910-917. · DOI · Paper page
  18. 28. Funch D, Gydesen H, Tornøe K, Major-Pedersen A, Chan KA (2014) A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metab 16: 273-275. · DOI · Paper page

Cited by

See all 50

Metadata

Authors
Terauchi, Y., Satoi, Y., Takeuchi, M., & Imaoka, T.
Venue
Endocrine Journal
Published
2014
Volume
61
Issue
10
Pages
949-959
ISSN
  • 0918-8959 (ISSN-L)
  • 1348-4540
OpenAlex
W2093375074
Cited by
50
References
11
FWCI
5.98
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1507/endocrj.ej14-0147
The paper
Terauchi, Y., Satoi, Y., Takeuchi, M., & Imaoka, T. (2014). Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocrine Journal. https://doi.org/10.1507/endocrj.ej14-0147

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.